July 14, 2020
BY EDGAR
Division of Corporation Finance
Office of Life Sciences
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Re: Generex Biotechnology Corporation
Form 10-K for the Fiscal Year Ended July 31, 2019
Filed November 12, 2019
File No. 000-25169
Ladies and Gentlemen:
We made the changes you requested in your July 7, 2020 comment letter to Generex Biotechnology Corporation (the “Company”) with respect to the above captioned matter. Enclosed are the Company’s proposed disclosure in the form of a Form 10-K/A (Amendment No.3). Kindly advise if changes are required.
Very truly yours,
GENEREX BIOTECHNOLOGY CORPORATION
Signature: /s/ Anthony Crisci
By: Anthony Crisci
Title: Chief Legal Officer